FDA Highlights Bioinformatics in Critical Path Priorities List; Will Software Vendors Benefit? | GenomeWeb

The US Food and Drug Administration has identified bioinformatics as one of six broad topics that promise to speed drug development while lowering costs before the end of the decade, but it is still unclear how informatics vendors can best take advantage of this newfound stature in the eyes of the regulatory agency.

Last week, the FDA released its Critical Path Opportunities List — a catalog of 76 initial projects that it described in a statement as "a starting point in identifying priorities to be accomplished under the Critical Path Initiative."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.